Nakamura A, Omori K, Terauchi Y. Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
Diabetes Obes Metab, in press
IF: 5.900
{ 326件 }
Nakamura A, Omori K, Terauchi Y. Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
Diabetes Obes Metab, in press
IF: 5.900
Araki T, Tone Y, Yamamoto M, Kameda H, Ben-Shlomo A, Yamada S, Takeshita A, Yamamoto M, Kawakami Y, Tone M, Melmed S Two Distinctive POMC Promoters Modify Gene Expression in Cushing’s Disease J Clin Endocrinol Metab, in press.
IF: 5.399（英文・原著）
Anders HJ and Nakazawa D
'Being an ADVOCATE for People with ANCA Vasculitis’
Clinical Journal of the American Society of Nephrology, in press.
IF: 6.628
第4回若手臨床内分泌医奨励賞（Clinical Endocrinology KO Rounds） Runners-Up賞 野本 博司先生
2021年度日本内分泌学会研究奨励賞 中村 昭伸先生
JCR2021 近未来のリウマチ医セッション 優秀ポスター賞 平石 直幹さん（学生） （指導医：垂水 政人先生）
第65回日本リウマチ学会総会・学術集会 ICW Excellent Abstract Award 工藤 友喜さん
Umeda M, Yoshida N, Hisada R, Burbano C, Orite SY, Kono M, Kyttaris VC, Krishfield S, Owen CA, Tsokos GC.
ADAM9 Enhances Th17 Cell Differentiation and Autoimmunity by Activating TGF-β1.
Proc Natl Acad Sci U S A. in press.
IF: 9.421
Sekizaki T, Kameda H, Nomoto H,Cho KY, Nakamura A, Takahashi K, Miyoshi A, Wada N, Takeuchi J, Nagai S, Miyoshi H, Atsumi T Dipeptidyl peptidase-4 inhibitor may exacerbate Graves’ disease: a multicenter observational study J Diabetes Investig, in press.
IF: 3.761
Yamauchi Y, Kameda H, Omori K, Tani M, Cho KY, Nakamura A, Miyoshi H,Tanaka S, Atsumi T.
Severe infection including disseminated herpes zoster triggered by subclinical Cushing’s disease: a case report BMC endocrine disorders, in press
IF:1.994